

# Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts

NCT04814446

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Assistance Publique - Hôpitaux de Paris
Enrollment	146 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Patients of age  $\geq$  15 years and 3 months with palmar or plantar warts (including periungueal and back of hands or feet warts) since more than one year with:
- $\leq 5$  warts (X palmar and X plantar) or
- $\leq 4$  cm<sup>2</sup> of Total surface involved by the warts (Y cm x Z cm).
- At total one month of application of topical salicylic acid, with minimum 3 weeks continuous.
- At least two sprays of liquid nitrogen (two applications at the same session, or at different sessions with a few intervals).
- ... and 5 more (see full listing online)

### Exclusion (16)

- Suspicion of COVID, with confirmation by autotest.
- Any causes of immunosuppression: organ transplant recipients, bone-marrow transplantation, immunosuppressive regimens for any diseases, HIV positivity.
- Women or men who received HPV Vaccine previously of the study;
- Any serious chronic or progressive disease according to the judgement of the investigator;
- Individuals with history of known allergies/hypersensitivity to any component of study vaccine;
- ... and 11 more (see full listing online)

## Locations (1 total)

---

Hospital Cochin, Paris, France